{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"66.9","upperLimit":"85.1","value":"76.9"},{"groupId":"OG001","lowerLimit":"63.6","upperLimit":"98.5","value":"88.2"},{"groupId":"OG002","lowerLimit":"71.0","upperLimit":"89.5","value":"81.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"91"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"76"}],"units":"Participants"}],"title":"KIF5B"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"54.9","upperLimit":"90.6","value":"76.0"},{"groupId":"OG001","lowerLimit":"19.4","upperLimit":"99.4","value":"75.0"},{"groupId":"OG002","lowerLimit":"60.4","upperLimit":"96.6","value":"84.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"CCDC6"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.5","upperLimit":"100","value":"100"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"title":"NCOA4"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.1","upperLimit":"80.8","value":"53.8"},{"comment":"The 95% CI was not estimable due to insufficient number of participants with events.","groupId":"OG001","lowerLimit":"NA","upperLimit":"NA","value":"0"},{"groupId":"OG002","lowerLimit":"30.8","upperLimit":"89.1","value":"63.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"11"}],"units":"Participants"}],"title":"Other"}],"denoms":[{"counts":[{"groupId":"OG000","value":"130"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"106"}],"units":"Participants"}],"description":"Oncogenic RET rearrangements have been identified in 1%-2% of NSCLC. These rearrangements typically produce chimeric transcripts that encode a fusion protein consisting of the RET kinase domain coupled to a protein with a dimerization domain (e.g., KIF5B, CCDC6, NCOA4). RET genotypes were determined by local testing and/or central analysis of ctDNA. CBR was assessed in participants having specific RET rearrangements. CBR was defined as the percentage of participants with a confirmed CR or PR, or stable disease (SD) which has been lasting at least 16 weeks (i.e. 4 cycles if 28 days are in one cycle) from the first dose date. CR and PR were defined per RECIST as outlined in the description for OM 3. SD was defined as neither sufficient shrinkage to qualify for CR or PR nor sufficient increase to qualify for PD. PD was defined as at least a 20% increase in SOD of target lesions, taking as reference the smallest SOD on study (including baseline).","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who had RET-fusion positive NSCLC previously treated with platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG000","title":"RET- Fusion Positive NSCLC With Prior Platinum Treatment"},{"description":"Participants who had RET-fusion positive NSCLC previously treated with non-platinum or systemic therapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG001","title":"RET-fusion Positive NSCLC With Non-platinum Systemic Treatment"},{"description":"Participants who had RET-fusion positive NSCLC not previously treated with systemic or platinum-based chemotherapies received pralsetinib, 400 mg orally, QD until discontinuation due to toxicity, disease progression, or other reasons.","id":"OG002","title":"RET-fusion Positive NSCLC With No Prior Systemic or Platinum Treatment"}],"paramType":"NUMBER","populationDescription":"RET-altered measurable disease population included participants in the efficacy population who have measurable (target) disease per RECIST v1.1, at baseline according to BICR and sufficient evidence of a RET alteration. As prespecified in the SAP, Phase 1 participants treated at 400 mg QD are pooled with Phase 2 participants for efficacy analysis. Number analyzed is the number of participants with the specified mutation.","reportingStatus":"POSTED","timeFrame":"Up to approximately 79.8 months","title":"Phase 1 and Phase 2: Clinical Benefit Rate (CBR) in RET-fusion Positive NSCLC Participants With Specific RET Gene Status","type":"SECONDARY","unitOfMeasure":"percentage of participants"}